Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer
Issued Date
2024-07-01
Resource Type
eISSN
20726694
Scopus ID
2-s2.0-85198496988
Journal Title
Cancers
Volume
16
Issue
13
Rights Holder(s)
SCOPUS
Bibliographic Citation
Cancers Vol.16 No.13 (2024)
Suggested Citation
O’Donnell C.D.J., Naleid N., Siripoon T., Zablonski K.G., Storandt M.H., Selfridge J.E., Hallemeier C.L., Conces M.L., Jethwa K.R., Bajor D.L., Thiels C.A., Warner S.G., Starlinger P.P., Atwell T.D., Mitchell J.L., Mahipal A., Jin Z. Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer. Cancers Vol.16 No.13 (2024). doi:10.3390/cancers16132407 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/99737
Title
Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer
Corresponding Author(s)
Other Contributor(s)
Abstract
(1) Background: Local therapies offer a potentially curative approach for patients with oligometastatic colorectal cancer (CRC). An evidence-based consensus recommendation for systemic therapy following definitive locoregional therapy is lacking. Tumor-informed circulating tumor DNA (ctDNA) might provide information to help guide management in this setting. (2) Methods: A multi-institutional retrospective study was conducted, including patients with CRC that underwent curative-intent locoregional therapy to an isolated site of metastatic disease, followed by tumor-informed ctDNA assessment. The Kaplan–Meier method and log-rank tests were used to compare disease-free survival based on ctDNA results. ctDNA test performance was compared to carcinoembryonic antigen (CEA) test results using McNemar’s test. (3) Results: Our study cohort consisted of 87 patients treated with locoregional interventions who underwent ctDNA testing. The initial ctDNA test post-intervention was positive in 28 patients and negative in 59 patients. The median follow-up time was 14.0 months. Detectable ctDNA post-intervention was significantly associated with early disease recurrence, with a median disease-free survival (DFS) of 6.63 months compared to 21.30 months in ctDNA-negative patients (p < 0.001). ctDNA detected a numerically higher proportion of recurrences than CEA (p < 0.097). Post-intervention systemic therapy was not associated with improved DFS (p = 0.745). (4) Conclusions: ctDNA results are prognostically important in oligometastatic CRC, and further prospective studies are urgently needed to define its role in guiding clinical decisions.